Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

This is a dose-finding study; therefore, there is no hypothesis testing

Key facts

Study ID

NCT00607048

Run by

Hoffmann-La Roche

People needed

34

Starts

2007-11-01

Expected to finish

2009-07-01

Last updated by the study team

2017-03-27

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate;
• Patients >18 years of age;
• Good performance status;
• Adequate bone marrow and organ function

You may not qualify if…

• Previous treatment with any other compound that targets CD40
• Current or planned concurrent treatment with any anticancer agent;
• Patients who have received bone marrow transplant;
• History of autoimmune disorder
• History (within the previous year) of heart failure or heart attack
• Cancer-associated coagulation disorders

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.